January 22nd 2021
Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.
Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.
Joleen M. Hubbard, MD, discusses sequencing challenges regarding EGFR inhibitors in colorectal cancer.
Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal cancer.
Toni K. Choueiri, MD, discusses the FDA approval of nivolumab and cabozantinib in metastatic renal cell carcinoma.
January 21st 2021
Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.
Balazs Halmos, MD, MS, discusses the emergence of KRAS-targeted therapies in lung cancer.
Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the potential of novel combination strategies with checkpoint inhibitors in oncology.
January 20th 2021
Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.
Shaji K. Kumar, MD, discusses the emergence of minimal residual disease negativity as a surrogate end point in relapsed/refractory multiple myeloma.